MYND Life Sciences Inc. News Releases

Management Cease Trade Order Status Report

Wed, 09 Apr 2025 12:37:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - Mynd Life Sciences Inc. (CNSX: MYND) ("Mynd" or the "Company") announced on March 3, 2025 the Company was granted a management cease trade order (MCTO) under the National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Company. The MCTO was granted as the Company had been advised by its external auditors (the "Auditors") that they will not be in a position to complete...

Management Cease Trade Order Status Report

Mon, 24 Mar 2025 21:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 24, 2025) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announced on March 3, 2025, the Company was granted a management cease trade order (MCTO) under the National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Company. The MCTO was granted as the Company had been advised by its external auditors (the "Auditors") that they will not be in a position to complete...

Management Cease Trade Order Granted

Mon, 03 Mar 2025 19:48:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - Mynd Life Sciences Inc. (CNSX: MYND) ("Mynd" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2024 (the "2024 Financial Statements") prior to the filing deadline of February 28, 2025 (the "Annual Filing Deadline") due to a delay in finalizing...

MYND Life Sciences Announces Shares for Debt Transaction

Tue, 11 Feb 2025 19:48:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2025) - MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that it has entered into shares for debt agreements (the "Agreements"), to satisfy an aggregate of $2,273,062.30 of the Company's outstanding debt (the...

MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share

Fri, 17 Jan 2025 19:30:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that the Board has approved the issuance of 4,000,001 common shares at $0.71/share in relation to the settlement of the $3.5 Million (CDN) of debenture announced...

MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition

Fri, 10 Jan 2025 00:29:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that the application to end its debenture has been successfully accepted by both the debenture holders and the regulatory commission. This announcement confirms the removal of $3.5 Million (CDN) of debt...

MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment

Fri, 22 Nov 2024 17:57:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a diagnostic biomarker test for depression which is being initially...

MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business

Tue, 12 Nov 2024 20:05:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 Million shares @ 0.71 per share to move $3.5 Million from its balance sheet, including the full restructure of an outstanding debenture on the...

MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.

Tue, 30 Jan 2024 16:30:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") The Company is pleased to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic...

MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer

Tue, 05 Dec 2023 19:56:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development company committed to advancing treatments for patients coping with chronic and acute neurological and inflammatory diseases, is delighted to announce the immediate appointment of Mr. John (Jay) Campbell as President and Chief Executive Officer.Mr. Campbell is distinguished for his expertise in financial...